FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of February 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
24 February 2026
Non-Executive Board Changes
AstraZeneca PLC announced today that Non-Executive Director Nazneen
Rahman will retire from the Board having joined in 2017. This will
take effect at the conclusion of the Company's AGM on 9 April
2026.
The Company also announced today that at the conclusion of the
Company's AGM on 9 April 2026:
● Tony Mok will succeed Nazneen Rahman as
Chair of the Sustainability Committee and become a member of the
Nomination and Governance Committee; and
● Birgit Conix will become a member of the
Sustainability Committee.
Michel Demaré, Chair of AstraZeneca, said "On behalf of the
whole Board, I would like to thank Nazneen Rahman for the
significant contributions she has made to our work as a Board, as
well as the insights, experience and leadership she brought to our
Board Committees. Nazneen has been with us since 2017 and we have
benefited from her specialist experience in genetics research and
translation, sustainable healthcare as well as her passion for open
science and science communication. Nazneen has been a member of the
Science Committee throughout her tenure, chairing it from 2017 to
2023, and has been Chair of the Sustainability Committee since its
establishment in 2021. She has also served on the Remuneration
Committee and Nomination and Governance Committees."
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date: 24 February 2026
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|